Erythromycin lactobionate
Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin lactobionate) is a small molecule pharmaceutical. Erythromycin lactobionate was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Erythrocin, Erythromycin lactobionate (discontinued: Erythrocin, Erythromycin, Erythromycin lactobionate)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| erythrocin lactobionate | ANDA | 2024-02-22 |
| erythrocin stearate | ANDA | 2015-07-31 |
| erythromycin lactobionate | ANDA | 2024-11-20 |
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF02: Erythromycin
— D10AF52: Erythromycin, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA01: Erythromycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA17: Erythromycin
HCPCS
Code | Description |
|---|---|
| J1364 | Injection, erythromycin lactobionate, per 500 mg |
Clinical
Clinical Trials
195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | 2 | 1 | 3 | 1 | 15 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 2 | 1 | 8 | 11 |
| Premature rupture fetal membranes | D005322 | — | O42 | — | — | 4 | 1 | 5 | 10 |
| Rupture | D012421 | — | — | — | — | 4 | 1 | 5 | 10 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | 1 | 6 | 8 |
| Communicable diseases | D003141 | — | — | — | 1 | — | 1 | 5 | 7 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | 2 | 1 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | 3 | 4 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 1 | 3 | 4 |
| Emergencies | D004630 | — | — | — | — | — | 1 | 2 | 3 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 3 | — | 5 | 8 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 2 | 2 | — | 5 | 8 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 3 | — | 1 | 5 |
| Gastrointestinal hemorrhage | D006471 | — | K92.2 | — | 1 | 3 | — | 1 | 5 |
| Lymphoma | D008223 | — | C85.9 | 1 | 3 | 1 | — | — | 4 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | 2 | 3 |
| Hypoventilation | D007040 | — | — | — | — | 1 | — | 2 | 3 |
| Chlamydia infections | D002690 | EFO_0007205 | A74.9 | — | 1 | 1 | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | — | 1 | 2 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 2 | 2 | — | — | 3 | 5 |
| Leukemia | D007938 | — | C95 | 2 | 2 | — | — | — | 4 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | 3 | 4 |
| Hypercapnia | D006935 | — | — | — | 1 | — | — | 3 | 4 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 3 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | 1 | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 2 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 2 |
Show 39 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosis | D012598 | — | — | 1 | — | — | — | 2 | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | 1 | 2 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 2 | — | — | — | — | 2 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 2 | — | — | — | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Precancerous conditions | D011230 | — | — | 1 | — | — | — | — | 1 |
| Oral leukoplakia | D007972 | HP_0002745 | K13.21 | 1 | — | — | — | — | 1 |
| Leukoplakia | D007971 | — | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 4 | 4 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 4 | 4 |
| Apnea | D001049 | — | R06.81 | — | — | — | — | 3 | 3 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | — | 3 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 2 | 2 |
| Bronchiectasis | D001987 | — | J47 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | — | 2 | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 2 | 2 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 2 | 2 |
Show 119 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Erythromycin lactobionate |
| INN | erythromycin |
| Description | Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 114-07-8 |
| RxCUI | 4053 |
| ChEMBL ID | CHEMBL1200506 |
| ChEBI ID | — |
| PubChem CID | 12560 |
| DrugBank | DB00199 |
| UNII ID | 63937KV33D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pfizer – Protalix BioTherapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 608 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,367 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use